Recent Updates
Recently added Catalysts
BIIB Negative Sentiment Score: 30/100

BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER ALERT: Only 7 Days Remain For Investors To Move For Lead Plaintiff in Biogen Inc.

Key Takeaway: Biogen Inc. is under scrutiny with a securities class action lawsuit alleging that the company overstated its efforts in transparency and corporate governance from February 3, 2022, to February 13, 2024. Shareholders have a limited timeline of only seven days to file for lead plaintiff status, which ends on July 22, 2024. This lawsuit poses potential financial consequences for Biogen and its investors, with no upfront costs for those wishing to participate in the litigation. Bernstein Liebhard LLP, the law firm handling the case, has a notable track record in recovering substantial amounts for clients.

Market Sentiment Analysis

CONCERNS & RISKS

  • Biogen is facing a securities class action lawsuit alleging overstated transparency and compliance.
  • The lawsuit could have potential financial implications for Biogen and its shareholders.
  • Only a limited time frame remains for investors to take action in the lawsuit.

Full Press Release Details

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP reminds shareholders that only 7 days remain to move for lead plaintiff in a securities class action lawsuit alleging claims on behalf of investors (the “Class”) who purchased or acquired the securities of Biogen Inc. (“Biogen”) (NASDAQ: BIIB) between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”).
If you wish to serve as lead plaintiff for the Class, you must file papers by July 22, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
For more information, submit a form at Biogen Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the deadline to file for lead plaintiff in the lawsuit?

The deadline to file for lead plaintiff is July 22, 2024.

What are the claims against Biogen in the lawsuit?

The lawsuit claims Biogen overstated its transparency and governance efforts.

Do shareholders have to pay fees for representation?

Shareholders pay no fees or expenses; representation is on a contingency basis.

Who can be a lead plaintiff in the class action?

Anyone who purchased Biogen securities during the class period can file.

How can I get more information about the lawsuit?

You can contact Investor Relations Manager Peter Allocco via email or phone.

Last updated: Jul 15, 2024